What is a durable response to immunotherapy — and could it happen to you?

A durable response means the shrinkage or disappearance of cancer seen on your scans after starting immunotherapy has continued well beyond the first check, not just shown up once. Trials typically start using the word at 12 months of an ongoing response, and reserve "long-term" for one still holding at 24 months or beyond.

It is a question that only applies after an initial response has already happened. Most people who ask about immunotherapy are not candidates for it at all, and among those who are, only a proportion respond in the first place — durable response describes what happens next for that smaller group, not a promise available to everyone weighing treatment.

The rest of this page sets out how common a durable response actually is, whether it can survive stopping treatment, and what it does and doesn't mean about your cancer being gone — without collapsing hope and false hope into the same sentence.

These are reporting thresholds used in published trials, not fixed biological cut-offs. Your own oncologist will tell you which definition applies to how your case is being tracked — a scan a few months short of a milestone is not a bad result.

Yes, in a meaningful minority of patients, though this is not the usual outcome and cannot be predicted for any one person in advance. Some patients who stop checkpoint inhibitor immunotherapy — after a planned fixed duration, due to side effects, or by choice — go on to show no cancer progression for years afterward, an outcome sometimes described as a treatment-free interval.

Deciding whether, and when, to stop maintenance treatment is not something a general information page can decide for you. Continuing on the current schedule, stopping at a point your oncologist recommends, and reducing frequency while monitoring closely are all real options weighed differently depending on how long you've been in response, your side-effect burden, and the evidence specific to your cancer type. What matters is that this is an explicit conversation with your treating oncologist — not a decision inferred from an average, and not one made alone.

No — and that gap between "durable response" and "cured" is exactly where hope tips into false hope if it isn't named plainly. A durable response means your cancer has stayed controlled on scans for a defined, extended period; it does not mean every cancer cell is confirmed gone, and no oncologist should present it as a cure.

It is genuinely good news that still comes with ongoing monitoring, not a finish line. Some patients with a long durable response go on to have very long-term control; others see the cancer return later, sometimes years afterward. Holding both facts at once — real good news, and continued watchfulness — is the honest way to sit with a durable response, rather than either dismissing it or treating it as a guarantee.

Late relapse — cancer returning after a long durable response, sometimes years later — does happen, which is why scheduled scans continue long after a response is first confirmed. It does not mean the earlier response "wasn't real" or that something was missed; it reflects that even a durable response describes control over time, not a permanent guarantee.

If it happens, the realistic next steps your oncology team will discuss honestly include a different treatment approach, a clinical trial where you're eligible, or care focused on comfort and quality of life. Restarting treatment, switching approach, or choosing supportive care instead are each legitimate paths depending on your case — not treating further is a real, respected option in this conversation, not a failure.

• Immunotherapy After Surgery: Why It Is Given When the Tumour Is Gone — if your immunotherapy started as adjuvant treatment, this explains why durability is judged differently than for measurable disease.
• Is Immunotherapy Painful? What the Treatment Actually Involves — what ongoing maintenance sessions actually feel like, month after month.
• Immunotherapy vs Targeted Therapy: They Are Not the Same — why durability patterns differ between these two approaches.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through long-term monitoring and maintenance decisions.

This page is for general information and does not replace a consultation. Duration-of-response figures are approximate, drawn from published follow-up data, and describe groups of patients — they are not a prediction of what will happen for any individual patient.

Thousands have asked this exact question before you

Wanting an honest answer instead of reassurance is not pessimism — it's how patients on maintenance treatment stay informed. Our team walks through your specific response history, honestly.